Incretin Atlas › Trials › SYNCHRONIZE-2 (obesity + T2D)
SYNCHRONIZE-2 (obesity + T2D)
Survodutide · t2d
Design
- Molecule(s)
- Survodutide
- Population
- t2d
- Official title
- A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
- Sponsor
- Boehringer Ingelheim
- Phase
- 3
- Registry status
- completed · 2023-11 → 2025-12
- Participants
- 755
- Duration
- 76 weeks
- Registry
- NCT06066528
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| survodutide 3.6 mg | t2d | 76 | — | −10.4 % vs −3.1 % Δ −7.3 pp | −8.2 % vs −3.9 % Δ −4.3 pp | −0.9 vs −0.2 | 26.4 vs 8.8 | 36.0 vs 30.7 | 47.6 vs 11.2 | 34.4 vs 5.6 | 9.2 vs 10.8 | −3.5 vs −2.7 | verified |
| survodutide 6.0 mg | t2d | 76 | — | −13.1 % vs −3.1 % Δ −10.0 pp | −9.8 % vs −3.9 % Δ −5.9 pp | −0.8 vs −0.2 | 25.9 vs 8.8 | 34.7 vs 30.7 | 57.4 vs 11.2 | 39.0 vs 5.6 | 8.4 vs 10.8 | −3.7 vs −2.7 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- survodutide 3.6 mg: Any discontinuation = 100 − % still on drug at week 76.
Verbatim quotes from the source (18)
- survodutide 3.6 mg · weight_eff · Results, Changes in Body Weight, paragraph 3
the mean change in body weight at week 76 was −10.4% with 3.6 mg of survodutide, –13.1% with 6.0 mg of survodutide, and –3.1% with placebo.
- survodutide 3.6 mg · weight_tp · Table 2
Mean change in body weight (95% CI) — % –8.2 (–9.2 to –7.2) –9.8 (–10.8 to –8.8) –3.9 (–4.9 to –2.9)
- survodutide 3.6 mg · ae_dc · Table 3
Adverse event leading to discontinuation of survodutide or placebo 66 (26.4) 65 (25.9) 22 (8.8)
- survodutide 3.6 mg · nausea · Table 3
Nausea 119 (47.6) 144 (57.4) 28 (11.2)
- survodutide 3.6 mg · vomiting · Table 3
Vomiting 86 (34.4) 98 (39.0) 14 (5.6)
- survodutide 3.6 mg · sae · Table 3
Any serious adverse event 23 (9.2) 21 (8.4) 27 (10.8)
- survodutide 3.6 mg · hba1c · Table 2
Mean change in glycated hemoglobin level — percentage points –0.9 –0.8 –0.2
- survodutide 3.6 mg · sbp · Table 2
Mean change in systolic blood pressure — mm Hg –3.5 –3.7 –2.7
- survodutide 3.6 mg · disc_any · Results, Participants (Fig. S2, Table S3)
and 66.2% were still receiving survodutide or placebo at 76 weeks (64.0%, 65.3%, and 69.3%, respectively)
- survodutide 6.0 mg · weight_eff · Results, Changes in Body Weight, paragraph 3
the mean change in body weight at week 76 was −10.4% with 3.6 mg of survodutide, –13.1% with 6.0 mg of survodutide, and –3.1% with placebo.
- survodutide 6.0 mg · weight_tp · Table 2
Mean change in body weight (95% CI) — % –8.2 (–9.2 to –7.2) –9.8 (–10.8 to –8.8) –3.9 (–4.9 to –2.9)
- survodutide 6.0 mg · ae_dc · Table 3
Adverse event leading to discontinuation of survodutide or placebo 66 (26.4) 65 (25.9) 22 (8.8)
- survodutide 6.0 mg · nausea · Table 3
Nausea 119 (47.6) 144 (57.4) 28 (11.2)
- survodutide 6.0 mg · vomiting · Table 3
Vomiting 86 (34.4) 98 (39.0) 14 (5.6)
- survodutide 6.0 mg · sae · Table 3
Any serious adverse event 23 (9.2) 21 (8.4) 27 (10.8)
- survodutide 6.0 mg · hba1c · Table 2
Mean change in glycated hemoglobin level — percentage points –0.9 –0.8 –0.2
- survodutide 6.0 mg · sbp · Table 2
Mean change in systolic blood pressure — mm Hg –3.5 –3.7 –2.7
- survodutide 6.0 mg · disc_any · Results, Participants (Fig. S2, Table S3)
and 66.2% were still receiving survodutide or placebo at 76 weeks (64.0%, 65.3%, and 69.3%, respectively)
Primary sources
- Wharton S, le Roux CW, Startseva E, Kloer IM, Alhussein A, Hussain SA, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. N Engl J Med. 2026. PMID: 42820639.
- ClinicalTrials.gov NCT06066528
How to cite this page
Medical Adviser's Group. Incretin Atlas: SYNCHRONIZE-2 (obesity + T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/synchronize-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.